|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
DK2683395T3
(en)
|
2011-03-11 |
2018-11-19 |
Hopitaux Paris Assist Publique |
USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
|
|
BR112013023151A2
(pt)
|
2011-03-11 |
2020-09-15 |
Assistance Publique - Hôpitaux De Paris |
interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9481866B2
(en)
*
|
2011-12-16 |
2016-11-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T cell populations enriched for stable regulatory T-cells
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
*
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
PT3102595T
(pt)
*
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
WO2015164815A1
(en)
*
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
PT3172227T
(pt)
*
|
2014-07-21 |
2019-12-06 |
Delinia Inc |
Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
|
|
AU2015301936B2
(en)
*
|
2014-08-11 |
2019-03-07 |
Delinia, Inc. |
Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
CR20170510A
(es)
*
|
2015-04-10 |
2018-02-26 |
Amgen Inc |
Muteínas de interuquina 2 para la expansión de células t regulatorias
|
|
CA2982362A1
(en)
*
|
2015-04-10 |
2016-10-13 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JP7422480B2
(ja)
*
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
WO2017201210A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
|
JP7325341B2
(ja)
|
2017-07-11 |
2023-08-14 |
シンソークス，インク． |
非天然ヌクレオチドの組み込み及びその方法
|
|
KR20240141853A
(ko)
*
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
EP3678677A4
(en)
*
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
IL275426B2
(en)
*
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
US12280118B2
(en)
|
2017-12-27 |
2025-04-22 |
Kyowa Kirin Co., Ltd. |
IL-2 variant
|
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
CN111918665B
(zh)
|
2018-03-28 |
2024-11-26 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US12403181B2
(en)
|
2018-08-13 |
2025-09-02 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
SG11202102930YA
(en)
|
2018-11-08 |
2021-04-29 |
Synthorx Inc |
Interleukin 10 conjugates and uses thereof
|
|
KR20210107714A
(ko)
|
2018-12-21 |
2021-09-01 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
인간 인터류킨-2 변이체 또는 이의 유도체
|
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
|
MA54955A
(fr)
|
2019-02-15 |
2021-12-22 |
Integral Molecular Inc |
Anticorps anti-claudine 6 et leurs utilisations
|
|
CN118388628A
(zh)
|
2019-03-29 |
2024-07-26 |
居里研究所 |
具有经修饰的生物活性的白介素-2变体
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
EP3980051A4
(en)
*
|
2019-06-05 |
2023-09-13 |
Asher Biotherapeutics, Inc. |
FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
PH12022550326A1
(en)
|
2019-08-13 |
2023-03-13 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
EP4013777A4
(en)
*
|
2019-08-15 |
2024-01-17 |
Cytimm Therapeutics, Inc. |
MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
|
|
EP4017540A1
(en)
|
2019-08-23 |
2022-06-29 |
Synthorx, Inc. |
Il-15 conjugates and uses thereof
|
|
US12234271B2
(en)
|
2019-09-10 |
2025-02-25 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
TW202128961A
(zh)
|
2019-11-20 |
2021-08-01 |
美商安維塔生物科學股份有限公司 |
細胞激素融合蛋白及其醫藥組合物及治療應用
|
|
BR112022011414A2
(pt)
|
2019-12-12 |
2022-08-30 |
Iltoo Pharma |
Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
|
|
IL293471A
(en)
|
2019-12-17 |
2022-08-01 |
Amgen Inc |
Dual interleukin-2 / tnf receptor agonist for use in medicine
|
|
WO2021127487A2
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
CA3165927A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
WO2021146436A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
CA3166009A1
(en)
*
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 muteins
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
PE20231648A1
(es)
|
2020-04-22 |
2023-10-17 |
Merck Sharp And Dohme Llc |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
|
|
WO2021222150A2
(en)
|
2020-04-28 |
2021-11-04 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
KR20230019889A
(ko)
|
2020-06-03 |
2023-02-09 |
아센디스 파마 온콜로지 디비전 에이/에스 |
Il-2 서열 및 이의 용도
|
|
AU2021310520A1
(en)
*
|
2020-07-14 |
2023-02-16 |
Pfizer Inc. |
Recombinant vaccinia virus
|
|
TW202219060A
(zh)
*
|
2020-08-28 |
2022-05-16 |
丹麥商阿森迪斯腫瘤製藥有限公司 |
醣基化il-2蛋白及其用途
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
JP2023548311A
(ja)
|
2020-10-29 |
2023-11-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
疾患の治療のための融合タンパク質
|
|
CN112279906B
(zh)
*
|
2020-10-30 |
2022-09-20 |
浙江新码生物医药有限公司 |
人白细胞介素2-聚乙二醇偶联物及其制备方法与应用
|
|
US20230398183A1
(en)
|
2020-11-13 |
2023-12-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
CN113321722A
(zh)
*
|
2021-04-13 |
2021-08-31 |
苏州复融生物技术有限公司 |
白介素2突变体及其应用
|
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
AU2022306974A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
|
|
EP4357357A4
(en)
|
2021-07-30 |
2025-01-08 |
Dracoterpin Biomedicine LLC |
HUMAN INTERLEUKIN-2 VARIANT AND ITS USE
|
|
CN118414160A
(zh)
|
2021-10-06 |
2024-07-30 |
艾尔图制药公司 |
对发炎组织具有靶向特异性的白介素2嵌合构建体
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4587043A1
(en)
|
2022-09-12 |
2025-07-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Interleukin-2 for use in treating autism spectrum disorder
|
|
TW202430574A
(zh)
|
2022-11-30 |
2024-08-01 |
美商積分分子股份有限公司 |
針對密連蛋白６之抗體，包括其雙特異性格式
|
|
JP2026503077A
(ja)
|
2023-01-09 |
2026-01-27 |
オデッセイ セラピューティクス，インコーポレイテッド |
抗ｔｎｆｒ２抗原結合タンパク質及びその使用
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025221954A1
(en)
|
2024-04-17 |
2025-10-23 |
Visterra, Inc. |
Use of il-2 variant for treating kidney transplant rejection
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
EP4707295A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|
|
EP4707296A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|